Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D
Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center, Zerifin, Israel.
Eur J Gynaecol Oncol. 2001;22(2):122-6.
The aim of this study was to determine whether immunohistochemical analysis of molecular parameters can provide an alternative method for classification of endometrial cancer cases according to their aggressiveness.
Sixty-four cases of endometrial carcinoma were assigned to three groups: group I--28 cases of endometrioid well and moderately differentiated (G1-G2) carcinoma; group II--14 cases of endometrioid poorly differentiated (G3) carcinoma; group III--22 cases of serous papillary endometrial cancer. Immunohistochemistry was used to determine the existence of estrogen receptors (ER), progesterone receptors (PR), and the expression of bcl-2, p53, HER-2/neu and Ki-67.
There was a significant difference in the immunohistochemical profile of the studied molecular parameters comparing the three study groups. The endometrioid G1-G2 cases (group I) were characterized by increased immunoreactivity for ER and PR (85.7% and 78.6%, respectively), increased immunoreactivity for bcl-2 (42.8%) and low expression of p53 (14.3%) and HER-2/neu (14.3%). In contrast to group I cases, the serous papillary endometrial cancer cases (group III) were characterized by immunonegativity for ER, PR and bcl-2 and high immunoreactivity for p53 (81.8%) and HER-2/neu (45.4%). The endometrioid G3 cases (group II) demonstrated an intermediate immunoprofile, characterized by immunonegativity for ER, PR and HER-2/neu, low immunoreactivity for bcl-2 (7.1%) and high expression of p53 (57.1%). The expression of Ki-67 did not differ significantly comparing the different cases of endometrial cancer.
This study provides evidence that the immunohistochemical analysis of endometrial carcinoma differentiates between different grades and histological types, thus being useful in the distinction of high risk cases.
本研究旨在确定分子参数的免疫组织化学分析是否可为根据子宫内膜癌病例的侵袭性进行分类提供一种替代方法。
64例子宫内膜癌病例被分为三组:第一组——28例子宫内膜样高分化和中分化(G1-G2)癌;第二组——14例子宫内膜样低分化(G3)癌;第三组——22例浆液性乳头状子宫内膜癌。采用免疫组织化学方法检测雌激素受体(ER)、孕激素受体(PR)的存在情况,以及bcl-2、p53、HER-2/neu和Ki-67的表达。
比较三个研究组,所研究分子参数的免疫组织化学特征存在显著差异。子宫内膜样G1-G2病例(第一组)的特征为ER和PR免疫反应性增加(分别为85.7%和78.6%),bcl-2免疫反应性增加(42.8%),p53(14.3%)和HER-2/neu(14.3%)低表达。与第一组病例相反,浆液性乳头状子宫内膜癌病例(第三组)的特征为ER、PR和bcl-2免疫阴性,p53(81.8%)和HER-2/neu(45.4%)免疫反应性高。子宫内膜样G3病例(第二组)表现出中间免疫特征,其特征为ER、PR和HER-2/neu免疫阴性,bcl-2免疫反应性低(7.1%),p53高表达(57.1%)。比较不同的子宫内膜癌病例,Ki-67的表达无显著差异。
本研究提供的证据表明,子宫内膜癌的免疫组织化学分析可区分不同分级和组织学类型,因此有助于鉴别高危病例。